Combination of Docetaxel + Estramustine + Hydrocortisone Versus Docetaxel + Prednisone in Patients With Advanced Prostate Cancer

Inclusion Criteria: * Histological or cytological confirmation of prostate adenocarcinoma * Advanced prostate carcinoma. * Previous treatment with hormones * Levels of testosterone \< 50 ng/dL * Good hematological, liver and kidney function * Previous treatment with surgery or radiotherapy, at least 4 weeks since end of treatment is allowed (the patient should have been recovered from any side effects. Exclusion Criteria: * Previous chemotherapy (estramustine included). * Second line hormonotherapy (oestrogens, gestagens, ketoconazole, ...included) * Previous treatment with radiotherapy (isotopes) or previous radiotherapy over \> 25% of the marrow * Any malignant process with a free disease interval under 5 years, exception done to non-melanoma skin cancer. * Concomitant serious diseases * Concomitant treatment with any other neoplassic therapy (exception done to LHRH agonists and/or biphosphonates). * Contraindication for the treatment with estramustine. * Previous history of pulmonary embolism, thromboembolic disease, previous treatment with anticoagulants (except aspirin), active thrombophlebitis or hypercoagulation. * Previous history of pulmonary spillage or ascitis. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.